Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689727 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
A Phase 2 study, sponsored by Endocyte.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01689727: Completed Phase 2 study, sponsored by Endocyte.
NCT01689727 is a Phase 2 study that has completed, run by Endocyte. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01689727, a Phase 2 study, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate receptor. The study is designed as an open-label, baseline-controlled study.
Interventions
- DRUG Technetium Tc 99m EC20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01689727
The ClinicalTrials.gov registry entry for NCT01689727 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Technetium Tc 99m EC20 is the first listed.
NCT01689727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01689727 about?
NCT01689727 is a clinical study titled "Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors". Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate receptor. The study is designed as an open-label, baseline-controlled s...
What is the current status of trial NCT01689727?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-09.
What interventions are being tested in trial NCT01689727?
The interventions under investigation include: Technetium Tc 99m EC20 (DRUG).
Who is sponsoring clinical trial NCT01689727?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.